Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

A Haiderali, M Huang and W Pan are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. KG Akers, D Maciel and AM Frederickson are employees of PRECISIONheor, a healthcare research consultancy that received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct the research described in this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comments (0)

No login
gif